Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 43
1946 190
1947 144
1948 130
1949 127
1950 1
1951 171
1952 366
1953 353
1954 350
1955 298
1956 224
1957 264
1958 247
1959 92
1960 4
1961 15
1962 18
1963 95
1964 166
1965 849
1966 2093
1967 3738
1968 5470
1969 7221
1970 8319
1971 9616
1972 11324
1973 12664
1974 13585
1975 11155
1976 9702
1977 10896
1978 11550
1979 12562
1980 11329
1981 11190
1982 13391
1983 16049
1984 14935
1985 15501
1986 15969
1987 17047
1988 19620
1989 21857
1990 23774
1991 23588
1992 23731
1993 23502
1994 24669
1995 25215
1996 25219
1997 26476
1998 27147
1999 26536
2000 29435
2001 31253
2002 33928
2003 37802
2004 40062
2005 42892
2006 45262
2007 46735
2008 49766
2009 51908
2010 54968
2011 60112
2012 63655
2013 65409
2014 65344
2015 67651
2016 65543
2017 65500
2018 63735
2019 63658
2020 55665
2021 37790
2022 9572
2023 6212
2024 5300

Text availability

Article attribute

Article type

Publication date

Search Results

1,566,766 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for pd ad
Search for PhD AD instead (1 results)
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS, Ou YC, Trotman J, Opat S. Tam CS, et al. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20. Expert Rev Clin Pharmacol. 2021. PMID: 34491123 Review.
Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, for the adverse effects seen with other BTK inhibitors.Areas covered: This drug profile covers zanubrutinib clinical pharmacology and …
Zanubrutinib was designed to achieve improved therapeutic concentrations and minimize off-target activities putatively accounting, in part, …
LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals.
Catorce MN, Gevorkian G. Catorce MN, et al. Curr Neuropharmacol. 2016;14(2):155-64. doi: 10.2174/1570159x14666151204122017. Curr Neuropharmacol. 2016. PMID: 26639457 Free PMC article. Review.
Neuroinflammation is an important feature in the pathogenesis and progression of neurodegenerative diseases such as Alzheimers disease (AD), Parkinsons disease (PD), frontotemporal dementia and amyotrophic lateral sclerosis. ...
Neuroinflammation is an important feature in the pathogenesis and progression of neurodegenerative diseases such as Alzheimers disease (A …
Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.
Dai L, Zou L, Meng L, Qiang G, Yan M, Zhang Z. Dai L, et al. Mol Neurobiol. 2021 May;58(5):2183-2201. doi: 10.1007/s12035-020-02232-6. Epub 2021 Jan 7. Mol Neurobiol. 2021. PMID: 33411241 Review.
Disorders of cholesterol metabolism in the brain are linked to neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and other atypical cognitive deficits that arise at old age. ...
Disorders of cholesterol metabolism in the brain are linked to neurodegenerative diseases, including Alzheimer's disease (AD), Parkin …
Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Saraiva C, et al. J Control Release. 2016 Aug 10;235:34-47. doi: 10.1016/j.jconrel.2016.05.044. Epub 2016 May 18. J Control Release. 2016. PMID: 27208862 Free article. Review.
In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged and more permeable BBB can pose serious challenges to drug delivery into the brain. ...In this review, we will discuss BB …
In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. Howev …
Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation.
Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Eleveld DJ, et al. Br J Anaesth. 2018 May;120(5):942-959. doi: 10.1016/j.bja.2018.01.018. Epub 2018 Mar 12. Br J Anaesth. 2018. PMID: 29661412 Free article.
BACKGROUND: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infusion (TCI) systems to determine the optimal drug administration to achieve a desired target concentration in a central or effect-site compartment. ...CONCLUSIONS: We d …
BACKGROUND: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infusion (TCI) systems to determine th …
Tools for predicting the PK/PD of therapeutic proteins.
Diao L, Meibohm B. Diao L, et al. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1115-25. doi: 10.1517/17425255.2015.1041917. Epub 2015 May 4. Expert Opin Drug Metab Toxicol. 2015. PMID: 25936400 Review.
INTRODUCTION: Assessments of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics are an integral part in the development of novel therapeutic agents. Compared with traditional small molecule drugs, therapeutic proteins possess many distinct PK/PD features th …
INTRODUCTION: Assessments of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics are an integral part in the development of n …
Astrocytes as targets for drug discovery.
Gorshkov K, Aguisanda F, Thorne N, Zheng W. Gorshkov K, et al. Drug Discov Today. 2018 Mar;23(3):673-680. doi: 10.1016/j.drudis.2018.01.011. Epub 2018 Jan 6. Drug Discov Today. 2018. PMID: 29317338 Free PMC article. Review.
Abnormalities in astrocytic functions have now been implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). ...
Abnormalities in astrocytic functions have now been implicated in the pathogenesis of neurodegenerative diseases, including Alzheimer's dise …
Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.
Han H, Yang Z, Chang SL, Li MD. Han H, et al. J Neuroimmune Pharmacol. 2018 Dec;13(4):467-478. doi: 10.1007/s11481-018-9806-5. Epub 2018 Sep 13. J Neuroimmune Pharmacol. 2018. PMID: 30215204 Free PMC article. Review.
Some biochemical pathways and physiological dysfunctions have been found to be shared by HAND and Alzheimer's (AD) or Parkinson's (PD) diseases, and nicotine may exert the same neuroprotection in HAND that has been observed in both AD and PD. ...
Some biochemical pathways and physiological dysfunctions have been found to be shared by HAND and Alzheimer's (AD) or Parkinson's ( …
Effects of Curcumin on Microglial Cells.
Ghasemi F, Bagheri H, Barreto GE, Read MI, Sahebkar A. Ghasemi F, et al. Neurotox Res. 2019 Jul;36(1):12-26. doi: 10.1007/s12640-019-00030-0. Epub 2019 Apr 4. Neurotox Res. 2019. PMID: 30949950 Review.
Excessive inflammation, however, leads to damaged neurons and neurodegenerative diseases (NDs), such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). ...
Excessive inflammation, however, leads to damaged neurons and neurodegenerative diseases (NDs), such as Parkinson's disease (PD), Alz …
Investigational drugs for atopic dermatitis.
Hon KL, Leung AKC, Leung TNH, Lee VWY. Hon KL, et al. Expert Opin Investig Drugs. 2018 Aug;27(8):637-647. doi: 10.1080/13543784.2018.1494723. Epub 2018 Jul 30. Expert Opin Investig Drugs. 2018. PMID: 30058384 Review.
There is little evidence that ceramides or natural moisturizing factors provide relief in AD. PDE4 inhibitors have shown promise as an effective topical treatment for mild-to-moderate AD with minimal adverse events, and dupilumab as an effective subcutaneous agent f …
There is little evidence that ceramides or natural moisturizing factors provide relief in AD. PDE4 inhibitors have shown promise as a …
1,566,766 results
You have reached the last available page of results. Please see the User Guide for more information.